|
621 |
Effect of opioids for breathlessness in heart failure: a systematic review and meta-analysis
Gärtner, Jan Rupert. - Freiburg : Universität, 2023
|
|
|
|
622 |
Effect of oral melatonin treatment on insulin resistance and diurnal blood pressure variability in night shift workers. A double-blind, randomized, placebo-controlled study
Hannemann, Juliane. - Aachen : Universitätsbibliothek der RWTH Aachen, 2023
|
|
|
|
623 |
Effects of add-on Celecoxib treatment on patients with schizophrenia spectrum disorders and inflammatory cytokine profile trial (TargetFlame): study design and methodology of a multicentre randomized, placebo-controlled trial
Strube, Wolfgang. - Augsburg : Universität Augsburg, 2023
|
|
|
|
624 |
Effects of empagliflozin on left ventricular diastolic function in addition to usual care in individuals with type 2 diabetes mellitus - results from the randomized, double-blind, placebo-controlled EmDia trial
Prochaska, Jürgen. - Freiburg : Universität, 2023
|
|
|
|
625 |
Effects of EPs 7630 on the duration of inability to work in acute bronchitis – a meta-analysis
Matthys, Heinrich. - Freiburg : Universität, 2023
|
|
|
|
626 |
Effects of specific bioactive collagen peptides in combination with concurrent training on running performance and indicators of endurance capacity in men: a randomized controlled trial
Jerger, Simon. - Freiburg : Universität, 2023
|
|
|
|
627 |
Effektivität verschiedener Placeboformen und Vergleich mit Verumtherapien in der Migräneprophylaxe bei Kindern und Jugendlichen
Lam, Thanh Lan. - München : Universitätsbibliothek der Ludwig-Maximilians-Universität, 2023
|
|
|
|
628 |
Efficacy and safety of an inactivated virus-particle vaccine for SARS-CoV-2, BIV1-CovIran
Mohraz, Minoo. - London : BMJ Publishing Group, 2023
|
|
|
|
629 |
Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy The MMPOWER-3 Randomized Clinical Trial
Karaa, Amel. - Ludwig-Maximilians-Universität München, 2023
|
|
|
|
630 |
Efficacy and safety of lenabasum, a cannabinoid type 2 receptor agonist, in a phase 3 randomized trial in diffuse cutaneous systemic sclerosis
Spiera, Robert. - Freiburg : Universität, 2023
|
|
Administration
